PRA023 monoclonal antibody.

PRA023 has tremendous possibilities for IBD and beyond

Our lead therapeutic candidate, PRA023, is a monoclonal antibody against cytokine TL1A, a target associated with both intestinal inflammation and fibrosis.

We’re now developing PRA023 for the treatment of Ulcerative Colitis, Crohn’s Disease, and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), along with companion diagnostic products designed to help predict responses to identify the right patients for PRA023, with the goal of ensuring maximal response.

Our biomarker-targeted therapeutic approach has the potential to advance a treatment paradigm similar to that pioneered in oncology, where the push for precision and increasingly targeted treatment has led to therapeutic decision-making based upon a patient’s biomarker profile—and transformed patient outcomes.


Opening up new possibilities by inhibiting TL1A activity
Currently in clinical trials, with great potential in multiple indications
Designed to transform the treatment paradigm in IBD and beyond

Clinical trials

We are conducting research on PRA023 and actively recruiting participants for the treatment of:

  • Ulcerative Colitis (UC)
  • Crohn’s Disease (CD)
  • Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Learn more about our research.

Prometheus Biosciences expanded access policy

Prometheus Biosciences is using a precision medicine approach to develop novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Clinical trials are necessary to obtain data on safety and efficacy that may support regulatory approval and the opportunity to offer wider access to patients. Currently, Prometheus Biosciences is not providing investigational drugs outside of our clinical trials. This policy may be revised in the future as the benefit-risk profile of each of our investigational drugs is evaluated based on evolving clinical data.